Oostenbrink J B, Rutten-van Mölken M P, Opdenoordt T S
Institute for Medical Technology Assessment, Erasmus University Rotterdam, The Netherlands.
Doc Ophthalmol. 1999;98(3):285-99. doi: 10.1023/a:1002453604171.
To determine the health care resource use and costs of patients with glaucoma or ocular hypertension in the Netherlands during the first 2 years after primary diagnosis, we performed a study based on retrospective chart review. Data of 200 patients and their health care resource use were collected in five hospitals. Unit-prices were calculated using micro costing in two hospitals. The mean 2-year costs per patient were estimated to be US$ 877. Outpatient visits to the ophthalmologist and medications were the cost-driving factors, and were responsible for 40 and 30% of total costs, respectively. Total costs were considered to be low, when compared to the estimated costs per patient in Sweden and the USA. In multiple least-squares regression only baseline IOP-value, the change in IOP-value between baseline and the next visit and the hospital of treatment were significantly related with total costs. The variation in costs between patients largely depended on whether or not a patient had undergone surgery.
为确定荷兰原发性青光眼或高眼压症患者在初次诊断后的头两年内的医疗资源使用情况及费用，我们开展了一项基于回顾性病历审查的研究。在五家医院收集了200名患者的数据及其医疗资源使用情况。在两家医院采用微观成本核算计算单位价格。估计每位患者两年的平均费用为877美元。眼科门诊就诊和药物是成本驱动因素，分别占总成本的40%和30%。与瑞典和美国每位患者的估计费用相比，总成本被认为较低。在多元最小二乘回归中，仅基线眼压值、基线与下次就诊之间的眼压值变化以及治疗医院与总成本显著相关。患者之间费用的差异很大程度上取决于患者是否接受过手术。
